Seegene announced on Jan. 24 its collaboration with Microsoft to promote a technology-sharing project aimed at realizing the vision of a “World Without Disease” during a meeting in London, the U.K.
Through this collaboration with Microsoft, Seegene plans to share its unique Syndromic Quantitative PCR technology with leading companies worldwide, accelerating the growth of its technology-sharing project that leads cross-industry innovation in the molecular diagnostics sector. Additionally, by expanding the number of participating companies in the global consortium, Seegene aims to provide optimal solutions to countries around the world, effectively responding to future pandemics and achieving a “world free of all diseases.”
Seegene will work with Microsoft’s Global Healthcare Team to connect partners and achieve this vision. They will also jointly participate in the annual symposium of the technology-sharing project and other key events that connect current and potential partners. Furthermore, Seegene plans to hold a declaration ceremony for scientists and other technology-sharing project partners in the first half of this year to commemorate their shared vision.
The technology-sharing project is a global strategy pursued by Seegene to create a world without disease. It enables scientists and experts worldwide to develop diagnostic reagents for various diseases in humans, animals, and plants using Seegene’s SGDDS system on-site. Seegene intends to share its Syndromic Quantitative PCR technology with about 100 national representative companies and global consortium partners, allowing local partner companies to take charge of product development, production, and sales.
Seegene’s SGDDS will incorporate Microsoft Azure, including the Azure OpenAI Service. The vast data generated by SGDDS will be used to facilitate data interaction and analysis for researchers, providing a Trusted Research Environment (TRE) that expands the boundaries of PCR research while protecting sensitive personal information and helping with compliance with local data regulations.
Furthermore, Microsoft Fabric, an AI-based unified analytics platform accessible to everyone, will also be introduced. This will enable Seegene to utilize data integration, data engineering, data science, data monitoring, real-time analytics, and business intelligence capabilities. Additionally, integrated AI-based services through Copilot for Microsoft 365 will be provided to enhance productivity, innovation, and creativity.
Seegene looks forward to exploring future collaborations with Microsoft in the medical sector, including joint research on next-generation PCR data management and analysis, with the goal of improving the healthcare ecosystem by providing accurate early disease diagnostics as a foundation for effective treatment and prevention.
Cheon Jong-yoon, CEO of Seegene, said, “Our strategic collaboration with Microsoft has enabled us to establish a more systematic technology-sharing business model. We expect the synergy from our cooperation to pave the way toward a world free from all diseases.”